WO2005107759A1 - Bh4反応性高フェニルアラニン血症治療剤 - Google Patents
Bh4反応性高フェニルアラニン血症治療剤 Download PDFInfo
- Publication number
- WO2005107759A1 WO2005107759A1 PCT/JP2005/008613 JP2005008613W WO2005107759A1 WO 2005107759 A1 WO2005107759 A1 WO 2005107759A1 JP 2005008613 W JP2005008613 W JP 2005008613W WO 2005107759 A1 WO2005107759 A1 WO 2005107759A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- granules
- granule
- preparation
- agent
- dry syrup
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2566433A CA2566433C (en) | 2004-05-11 | 2005-05-11 | Therapeutic agent for bh4-responsive hyperphenylalaninemia |
JP2006513041A JP4964587B2 (ja) | 2004-05-11 | 2005-05-11 | Bh4反応性高フェニルアラニン血症治療剤 |
EP05739251A EP1757293B1 (en) | 2004-05-11 | 2005-05-11 | Bh4-responsive hyperphenylalaninemia remedies |
ES05739251T ES2393785T3 (es) | 2004-05-11 | 2005-05-11 | Remedios para hiperfenilalaninemia sensible a BH4 |
DK05739251.6T DK1757293T3 (da) | 2004-05-11 | 2005-05-11 | Bh4-responsiv hyperphenylalaninæmi-medikamenter |
US11/579,928 US20080207624A1 (en) | 2004-05-11 | 2005-05-11 | Therapeutic Agent for Bh4-Responsive Hyperphenylalaninemia |
AU2005239939A AU2005239939C1 (en) | 2004-05-11 | 2005-05-11 | BH4-responsive hyperphenylalaninemia remedies |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-141615 | 2004-05-11 | ||
JP2004141615 | 2004-05-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005107759A1 true WO2005107759A1 (ja) | 2005-11-17 |
Family
ID=35320030
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/008613 WO2005107759A1 (ja) | 2004-05-11 | 2005-05-11 | Bh4反応性高フェニルアラニン血症治療剤 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20080207624A1 (ja) |
EP (1) | EP1757293B1 (ja) |
JP (1) | JP4964587B2 (ja) |
AU (1) | AU2005239939C1 (ja) |
CA (1) | CA2566433C (ja) |
DK (1) | DK1757293T3 (ja) |
ES (1) | ES2393785T3 (ja) |
WO (1) | WO2005107759A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007238451A (ja) * | 2006-03-03 | 2007-09-20 | Elmed Eisai Kk | 医薬組成物及びその製造方法 |
US7566462B2 (en) | 2004-11-17 | 2009-07-28 | Biomarin Pharmaceutical Inc. | Stable tablet formulation |
JP2011530540A (ja) * | 2008-08-12 | 2011-12-22 | オルファ スイス ゲーエムベーハー | テトラヒドロビオプテリンを含有する医薬剤形 |
JP2012197266A (ja) * | 2011-03-04 | 2012-10-18 | Daiichi Sankyo Healthcare Co Ltd | セチリジン塩酸塩を含有する医薬組成物 |
US9216178B2 (en) | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
JP2020507570A (ja) * | 2017-02-13 | 2020-03-12 | バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Animal Health Gmbh | プラドフロキサシンを含有する液体組成物 |
JP2020132586A (ja) * | 2019-02-21 | 2020-08-31 | アサヒグループ食品株式会社 | アミノ酸又はその塩及びビタミンc含有組成物の変色抑制方法、並びに粉末組成物、顆粒、及び錠剤 |
JP7443663B2 (ja) | 2018-11-07 | 2024-03-06 | ディーエスエム アイピー アセッツ ビー.ブイ. | 改善された流動性を示す、リボフラビンを含有する薬剤 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1708690B1 (en) | 2003-11-17 | 2016-07-20 | BioMarin Pharmaceutical Inc. | Treatment of phenylketonuria with bh4 |
PT2139485E (pt) | 2007-04-11 | 2013-01-16 | Biomarin Pharm Inc | Métodos de administração da tetra-hidrobiopterina, composições associadas e métodos de medição |
RU2661033C9 (ru) * | 2011-03-01 | 2018-10-23 | Дифарма С.А. | Стабильные композиции тетрагидробиоптерина |
DK2926805T3 (en) * | 2014-03-31 | 2016-07-25 | Vasopharm Gmbh | Solid pharmaceutical compositions comprising biopterine derivatives and uses of such compositions |
TR201914416A1 (tr) * | 2019-09-23 | 2021-04-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Sapropteri̇n di̇hi̇droklorürün efervesan formülasyonlari |
CN112057423A (zh) * | 2020-10-21 | 2020-12-11 | 兆科药业(广州)有限公司 | 一种含有盐酸沙丙蝶呤的颗粒剂药物及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999016470A1 (fr) * | 1997-09-30 | 1999-04-08 | Daiichi Pharmaceutical Co., Ltd. | Preparation orale |
JP2003277265A (ja) * | 2002-03-22 | 2003-10-02 | Daiichi Suntory Pharma Co Ltd | eNOS発現に起因する疾患の予防または治療薬 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996003989A1 (fr) * | 1994-08-05 | 1996-02-15 | Suntory Limited | Remede contre la degenerescence spino-cerebelleuse |
GB0110846D0 (en) * | 2001-05-02 | 2001-06-27 | Phoqus Ltd | Tablets with coloured patterns |
CA2581814C (en) * | 2004-11-17 | 2015-10-13 | Biomarin Pharmaceutical Inc. | Stable tablet formulation of tetrahydrobiopterin |
-
2005
- 2005-05-11 US US11/579,928 patent/US20080207624A1/en not_active Abandoned
- 2005-05-11 EP EP05739251A patent/EP1757293B1/en active Active
- 2005-05-11 AU AU2005239939A patent/AU2005239939C1/en active Active
- 2005-05-11 CA CA2566433A patent/CA2566433C/en active Active
- 2005-05-11 JP JP2006513041A patent/JP4964587B2/ja active Active
- 2005-05-11 DK DK05739251.6T patent/DK1757293T3/da active
- 2005-05-11 WO PCT/JP2005/008613 patent/WO2005107759A1/ja active Application Filing
- 2005-05-11 ES ES05739251T patent/ES2393785T3/es active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999016470A1 (fr) * | 1997-09-30 | 1999-04-08 | Daiichi Pharmaceutical Co., Ltd. | Preparation orale |
JP2003277265A (ja) * | 2002-03-22 | 2003-10-02 | Daiichi Suntory Pharma Co Ltd | eNOS発現に起因する疾患の予防または治療薬 |
Non-Patent Citations (3)
Title |
---|
"Biopten Karyu 2.5%.", 2003, XP002994296, Retrieved from the Internet <URL:http://www.maruho.co.jp/medical/pdf/te/bpt_te.pdf> [retrieved on 20050811] * |
"Iryoyaku Nippon Iyakuhinshu.", 2000, NIPPON IYAKU JOHO CENTER., pages: 735 - 736, XP002994295 * |
"Japan Pharmaceutical Excipients Council, Iyaku Tenkabutsu Jiten Tsuiho.", 1995, pages 151 - 152, XP002994297 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7566462B2 (en) | 2004-11-17 | 2009-07-28 | Biomarin Pharmaceutical Inc. | Stable tablet formulation |
JP2007238451A (ja) * | 2006-03-03 | 2007-09-20 | Elmed Eisai Kk | 医薬組成物及びその製造方法 |
JP2011530540A (ja) * | 2008-08-12 | 2011-12-22 | オルファ スイス ゲーエムベーハー | テトラヒドロビオプテリンを含有する医薬剤形 |
JP2012197266A (ja) * | 2011-03-04 | 2012-10-18 | Daiichi Sankyo Healthcare Co Ltd | セチリジン塩酸塩を含有する医薬組成物 |
US9216178B2 (en) | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
JP2020507570A (ja) * | 2017-02-13 | 2020-03-12 | バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Animal Health Gmbh | プラドフロキサシンを含有する液体組成物 |
US11617792B2 (en) | 2017-02-13 | 2023-04-04 | Bayer Animal Health Gmbh | Liquid composition containing pradofloxacin |
JP7257322B2 (ja) | 2017-02-13 | 2023-04-13 | バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | プラドフロキサシンを含有する液体組成物 |
JP7443663B2 (ja) | 2018-11-07 | 2024-03-06 | ディーエスエム アイピー アセッツ ビー.ブイ. | 改善された流動性を示す、リボフラビンを含有する薬剤 |
JP2020132586A (ja) * | 2019-02-21 | 2020-08-31 | アサヒグループ食品株式会社 | アミノ酸又はその塩及びビタミンc含有組成物の変色抑制方法、並びに粉末組成物、顆粒、及び錠剤 |
JP7330716B2 (ja) | 2019-02-21 | 2023-08-22 | アサヒグループ食品株式会社 | アミノ酸又はその塩及びビタミンc含有組成物の変色抑制方法、並びに粉末組成物、顆粒、及び錠剤 |
Also Published As
Publication number | Publication date |
---|---|
DK1757293T3 (da) | 2012-10-22 |
JP4964587B2 (ja) | 2012-07-04 |
CA2566433A1 (en) | 2005-11-17 |
JPWO2005107759A1 (ja) | 2008-03-21 |
AU2005239939C1 (en) | 2011-06-30 |
ES2393785T3 (es) | 2012-12-28 |
CA2566433C (en) | 2013-02-19 |
EP1757293A1 (en) | 2007-02-28 |
EP1757293A4 (en) | 2011-06-08 |
EP1757293B1 (en) | 2012-10-10 |
AU2005239939A1 (en) | 2005-11-17 |
US20080207624A1 (en) | 2008-08-28 |
AU2005239939B2 (en) | 2011-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005107759A1 (ja) | Bh4反応性高フェニルアラニン血症治療剤 | |
WO2018077310A1 (zh) | 一种含维生素c钠的泡腾片及其制备方法 | |
TW499311B (en) | Oral dosage form of azithromycin not exhibiting an adverse food effect | |
US20190269614A1 (en) | Chewable tablet containing vitamin c sodium and preparation method thereof | |
US4950654A (en) | Hydrophilic theophylline powder formulation and its preparation | |
EP1707192B1 (en) | Pharmaceutical composition | |
US20090226408A1 (en) | Anti-fatigue composition | |
JP2011530540A (ja) | テトラヒドロビオプテリンを含有する医薬剤形 | |
US20070293572A1 (en) | Anti-Fatigue Composition | |
CN107375322B (zh) | 儿童及青少年型多种维生素矿物质泡腾片及其制备方法 | |
WO2019208540A1 (ja) | 安定性に優れた固形製剤 | |
KR100927254B1 (ko) | 분지쇄 아미노산을 포함하는 액상 조성물 및 이의 제조방법 | |
WO2005072717A1 (ja) | ビグアナイド系薬物の内服製剤 | |
ES2763321T3 (es) | Premezcla y composición farmacéutica para la administración oral de memantina como una suspensión permanente o de preparación previa a la administración al paciente, optativamente por sonda de alimentación enteral y procedimientos correspondientes | |
JP6590436B1 (ja) | 安定性に優れた固形製剤 | |
US20220312813A1 (en) | Formulation for iron supplements | |
KR19980701912A (ko) | 트리메부틴을 함유하는 신규 제약 조성물 및 그 제조 방법 | |
CN107149594A (zh) | 一种醋酸钙掩味颗粒及其制备方法 | |
WO2006024241A1 (es) | Preparado de hierro iónico e hierro hemínico y sus variantes en la profilaxis y tratamiento de la deficiencia de hierro | |
ES2870582T3 (es) | Composición | |
ES2943432B2 (es) | Composiciones que contienen una sal mineral para uso oral | |
Sabri | Folic acid Granulation and Evaluation for pediatric diseases | |
WO2020215238A1 (zh) | 一种可溶于水的碳酸钙d 3制剂 | |
JP2003192574A (ja) | 弱アルカリで安定化される薬剤を含む医薬用液剤 | |
CN116635013A (zh) | 口腔可分散的粉末组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006513041 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005239939 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005739251 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2566433 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
ENP | Entry into the national phase |
Ref document number: 2005239939 Country of ref document: AU Date of ref document: 20050511 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005239939 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005739251 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11579928 Country of ref document: US |